

Gerard Espinosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7820441/publications.pdf>

Version: 2024-02-01

416
papers

13,991
citations

14655

66
h-index

32842

100
g-index

446
all docs

446
docs citations

446
times ranked

10463
citing authors

#	ARTICLE	IF	CITATIONS
1	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1011-1018.	0.9	610
2	Catastrophic Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2001, 80, 355-377.	1.0	342
3	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 2568-2576.	6.7	294
4	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1428-1432.	0.9	262
5	Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 456-459.	0.9	236
6	Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. <i>Autoimmunity Reviews</i> , 2013, 12, 1085-1090.	5.8	211
7	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <i>Autoimmunity Reviews</i> , 2016, 15, 1120-1124.	5.8	211
8	Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1205-1209.	0.9	209
9	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
10	Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. <i>Arthritis and Rheumatism</i> , 2010, 62, 1147-1152.	6.7	176
11	Adrenal Involvement in the Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2003, 82, 106-118.	1.0	175
12	Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 655.	7.4	166
13	Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. <i>American Journal of Medicine</i> , 2002, 112, 37-43.	1.5	163
14	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1312-1317.	0.9	161
15	Etiopathogenesis of Behçet's disease. <i>Autoimmunity Reviews</i> , 2010, 9, 241-245.	5.8	161
16	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526-531.	0.9	157
17	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , 2015, 2, e000123-e000123.	2.7	155
18	Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms. <i>Autoimmunity Reviews</i> , 2010, 10, 74-79.	5.8	152

#	ARTICLE	IF	CITATIONS
19	The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2018, 92, 1-11.	6.5	143
20	Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 730-736.	0.9	133
21	Long term outcome of catastrophic antiphospholipid syndrome survivors. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 530-533.	0.9	126
22	The lung in the antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 195-198.	0.9	123
23	Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 322-332.	3.4	122
24	Successful Treatment with Posaconazole of a Patient with Chronic Chagas Disease and Systemic Lupus Erythematosus. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 583-587.	1.4	121
25	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. <i>Autoimmunity Reviews</i> , 2015, 14, 387-395.	5.8	121
26	Analysis of patient flow in the emergency department and the effect of an extensive reorganisation. <i>Emergency Medicine Journal</i> , 2003, 20, 143-148.	1.0	120
27	Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , 2006, 5, 180-186.	5.8	115
28	Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 1999, 29, 182-190.	3.4	114
29	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <i>Autoimmunity Reviews</i> , 2015, 14, 153-159.	5.8	106
30	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	5.8	106
31	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. <i>Human Molecular Genetics</i> , 2013, 22, 4021-4029.	2.9	104
32	Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. <i>Acta Ophthalmologica</i> , 2015, 93, 561-567.	1.1	104
33	Tocilizumab treatment for refractory uveitis-related cystoid macular edema. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2627-2632.	1.9	103
34	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	12.8	100
35	The. <i>Rare Diseases of the Immune System</i> , 2015, , 249-262.	0.1	98
36	Transverse Myelitis Affecting More Than 4 Spinal Segments Associated with Systemic Lupus Erythematosus: Clinical, Immunological, and Radiological Characteristics of 22 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 246-256.	3.4	97

#	ARTICLE	IF	CITATIONS
37	Immunosuppression and Chagas Disease: A Management Challenge. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e1965.	3.0	97
38	Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2001, 80, 345-354.	1.0	95
39	McMaster RAREâ€œBestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1656-1664.	3.8	95
40	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. <i>Lupus</i> , 2011, 20, 174-181.	1.6	93
41	Current treatment of antiphospholipid syndrome: lights and shadows. <i>Nature Reviews Rheumatology</i> , 2015, 11, 586-596.	8.0	93
42	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. <i>Lupus</i> , 2011, 20, 165-173.	1.6	91
43	Trends in Illicit Drug Emergencies: The Emerging Role of Gamma-Hydroxybutyrate. <i>Journal of Toxicology: Clinical Toxicology</i> , 2002, 40, 129-135.	1.5	89
44	Sedation for cardioversion in the emergency department. <i>Annals of Emergency Medicine</i> , 2003, 42, 767-772.	0.6	89
45	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 740-746.	0.9	89
46	Young Onset of Primary SjÃ¶gren's syndrome: clinical and immunological characteristics. <i>Lupus</i> , 1998, 7, 202-206.	1.6	88
47	Pediatric catastrophic antiphospholipid syndrome: Descriptive analysis of 45 patients from the â€œCAPS Registryâ€œ. <i>Autoimmunity Reviews</i> , 2014, 13, 157-162.	5.8	88
48	Adalimumab for the treatment of Behcet's disease: experience in 19 patients. <i>Rheumatology</i> , 2012, 51, 1825-1831.	1.9	87
49	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. <i>Autoimmunity Reviews</i> , 2006, 6, 72-75.	5.8	83
50	Hepatitis C virus infection in 'primary' Sjogren's syndrome: prevalence and clinical significance in a series of 90 patients. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 173-175.	0.9	82
51	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
52	Update on the Catastrophic Antiphospholipid Syndrome and the â€œCAPS Registryâ€œ. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 333-338.	2.7	79
53	Neuropsychiatric systemic lupus erythematosus: Magnetic resonance imaging findings and correlation with clinical and immunological features. <i>Autoimmunity Reviews</i> , 2013, 12, 1166-1170.	5.8	77
54	The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. <i>Journal of Rheumatology</i> , 2007, 34, 346-52.	2.0	77

#	ARTICLE	IF	CITATIONS
55	Myelodysplastic and Myeloproliferative Syndromes Associated with Giant Cell Arteritis and Polymyalgia Rheumatica: A Coincidental Coexistence or a Causal Relationship?. <i>Clinical Rheumatology</i> , 2002, 21, 309-313.	2.2	75
56	Management of refractory cases of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2011, 10, 664-668.	5.8	75
57	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 454-462.	0.9	75
58	Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 943-946.	0.9	74
59	Registry of the Spanish Network for Systemic Sclerosis. <i>Medicine (United States)</i> , 2015, 94, e1728.	1.0	73
60	Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: A prospective, long-term, followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 460-467.	6.7	72
61	Behçet Disease-associated Uveitis Successfully Treated with Golimumab. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 160-162.	1.8	71
62	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014, 53, 275-284.	1.9	71
63	Antiphospholipid syndrome: pathogenic mechanisms. <i>Autoimmunity Reviews</i> , 2003, 2, 86-93.	5.8	70
64	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , 2018, 57, 1264-1270.	1.9	70
65	TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. <i>Retina</i> , 2018, 38, 1361-1370.	1.7	70
66	The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 2349-2358.	6.7	69
67	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. <i>Nature Communications</i> , 2021, 12, 3523.	12.8	67
68	The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 81-86.	0.9	66
69	Intestinal Involvement Secondary to the Antiphospholipid Syndrome (APS): Clinical and Immunologic Characteristics of 97 Patients: Comparison of Classic and Catastrophic APS1. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 36, 287-296.	3.4	63
70	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.9	63
71	Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 366-372.	3.4	62
72	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.	5.8	62

#	ARTICLE	IF	CITATIONS
73	Early- versus Late-Onset Systemic Sclerosis. <i>Medicine (United States)</i> , 2014, 93, 73-81.	1.0	61
74	Factors influencing polyautoimmunity in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2010, 9, 229-232.	5.8	60
75	Epidemiology and management of refractory lupus nephritis. <i>Autoimmunity Reviews</i> , 2011, 10, 655-663.	5.8	60
76	Morbidity and Mortality in the Catastrophic Antiphospholipid Syndrome: Pathophysiology, Causes of Death, and Prognostic Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 290-294.	2.7	58
77	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 10, 679-684.	5.8	58
78	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 602-607.	0.9	56
79	Cardiac toxicity secondary to long term treatment with chloroquine. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 301-302.	0.9	55
80	Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. <i>British Journal of Rheumatology</i> , 2005, 44, 95-99.	2.3	55
81	Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 61-66.	0.9	55
82	Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. <i>Arthritis Research and Therapy</i> , 2013, 15, R41.	3.5	55
83	Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. <i>Nature Reviews Rheumatology</i> , 2010, 6, 296-300.	8.0	54
84	Catastrophic Antiphospholipid Syndrome. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 157-165.	0.9	53
85	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	1.9	53
86	The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. <i>Lupus</i> , 2009, 18, 905-912.	1.6	51
87	Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. <i>Autoimmunity Reviews</i> , 2017, 16, 750-755.	5.8	51
88	Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 154-158.	1.4	50
89	HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population. <i>Arthritis Research and Therapy</i> , 2013, 15, R145.	3.5	50
90	Effects of external and internal factors on emergency department overcrowding. <i>Annals of Emergency Medicine</i> , 2002, 39, 693-695.	0.6	49

#	ARTICLE	IF	CITATIONS
91	Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. <i>Immunologic Research</i> , 2013, 56, 358-361.	2.9	48
92	Genetic Analysis with the ImmunoChip Platform in Behçet Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci. <i>PLoS ONE</i> , 2016, 11, e0161305.	2.5	48
93	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. <i>Frontiers in Immunology</i> , 2020, 11, 865.	4.8	48
94	Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2001, 31, 12-20.	3.4	47
95	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.	1.9	47
96	Catastrophic APS in the Context of Other Thrombotic Microangiopathies. <i>Current Rheumatology Reports</i> , 2015, 17, 482.	4.7	46
97	Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. <i>Lupus</i> , 2007, 16, 366-373.	1.6	45
98	Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. <i>Intensive Care Medicine</i> , 2007, 33, 1354-1362.	8.2	45
99	Catastrophic antiphospholipid syndrome and sepsis. A common link?. <i>Journal of Rheumatology</i> , 2007, 34, 923-6.	2.0	45
100	Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 80-84.	6.5	44
101	Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. <i>Haematologica</i> , 2000, 85, 632-7.	3.5	43
102	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 408-411.	5.3	42
103	Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. <i>International Ophthalmology</i> , 2010, 30, 577-581.	1.4	42
104	Adrenal involvement in the antiphospholipid syndrome. <i>Lupus</i> , 2003, 12, 569-572.	1.6	41
105	Allelic Diversity and Affinity Variants of MICA are Imbalanced in Spanish Patients with Behçet's Disease. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 77-82.	2.7	39
106	Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 721-729.	1.6	39
107	Catastrophic antiphospholipid syndrome: The current management approach. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 239-249.	3.3	39
108	Identification of a natural soluble form of human CD5. <i>Tissue Antigens</i> , 1999, 54, 128-137.	1.0	38

#	ARTICLE	IF	CITATIONS
109	Current and future treatments for Behçet's uveitis: road to remission. <i>International Ophthalmology</i> , 2014, 34, 365-381.	1.4	38
110	Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. <i>Autoimmunity Reviews</i> , 2015, 14, 586-593.	5.8	38
111	Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 124-131.	3.4	37
112	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. <i>Arthritis Research and Therapy</i> , 2014, 16, R6.	3.5	37
113	“Non-criteria” antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , 2020, 19, 102689.	5.8	37
114	ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Noninfectious Systemic Inflammatory Response Syndrome. <i>Shock</i> , 2015, 43, 556-562.	2.1	35
115	Auscultation of Velcro Crackles is Associated With Usual Interstitial Pneumonia. <i>Medicine (United States)</i> 2014; 93(14):e43. doi:10.1093/med/93.14.e43	1.0	35
116	Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	2.0	34
117	Relapsing Catastrophic Antiphospholipid Syndrome Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 417-423.	3.4	34
118	Catastrophic antiphospholipid syndrome: an update. <i>Panminerva Medica</i> , 2017, 59, 254-268.	0.8	34
119	Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the CAPS Registry. <i>Autoimmunity Reviews</i> , 2022, 21, 103055.	5.8	34
120	Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 835-840.	0.9	33
121	Solid cancer, antiphospholipid antibodies, and venous thromboembolism. <i>Autoimmunity Reviews</i> , 2011, 10, 222-227.	5.8	33
122	Advanced MRI techniques: biomarkers in neuropsychiatric lupus. <i>Lupus</i> , 2017, 26, 510-516.	1.6	33
123	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	3.5	32
124	Cardiac valve replacement in patients with antiphospholipid syndrome. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	3.4	32
125	Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2013, 12, 607-616.	5.8	32
126	Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. <i>Lupus</i> , 2018, 27, 2253-2261.	1.6	32

#	ARTICLE	IF	CITATIONS
127	Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. <i>Clinical and Experimental Rheumatology</i> , 1997, 15, 143-9.	0.8	32
128	Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995-2015) from a single referral centre in Catalonia. <i>Lupus</i> , 2019, 28, 1158-1166.	1.6	31
129	Optic neuropathy in the "primary" antiphospholipid syndrome: Report of a case and review of the literature. <i>Clinical Rheumatology</i> , 1997, 16, 629-631.	2.2	30
130	Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. <i>Autoimmunity Reviews</i> , 2006, 6, 81-84.	5.8	30
131	Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behçet's disease. <i>Human Immunology</i> , 2013, 74, 230-233.	2.4	30
132	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.9	30
133	Epistatic Interaction of ERAP1 and HLA-B in Behçet Disease: A Replication Study in the Spanish Population. <i>PLoS ONE</i> , 2014, 9, e102100.	2.5	30
134	Proinflammatory Cytokines and C-Reactive Protein in Uveitis Associated with Behçet's Disease. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	30
135	Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1582-1592.	1.9	29
136	Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach. <i>Scientific Reports</i> , 2017, 7, 8453.	3.3	29
137	Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 68-71.	5.8	28
138	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. <i>Rheumatology</i> , 2011, 50, 1976-1981.	1.9	27
139	High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis. <i>Medicine (United States)</i> 2017; 96(10):e52777. doi:10.1093/med/96.10.e52777	1.0	27
140	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 999-1009.	2.2	27
141	Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1839-1862.	2.5	27
142	Delayed lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1044-1046.	0.9	26
143	Epidemiology and clinical outcomes of bloodstream infections among lupus patients. <i>Lupus</i> , 2011, 20, 965-971.	1.6	26
144	Catastrophic Antiphospholipid Syndrome. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 391-400.	1.4	26

#	ARTICLE	IF	CITATIONS
145	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. <i>Lupus</i> , 2016, 25, 864-872.	1.6	26
146	Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. <i>Lupus</i> , 2002, 11, 730-735.	1.6	25
147	Catastrophic Antiphospholipid Syndrome: Lessons from the "CAPS Registry" A Tribute to the Late Josep Font. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 448-456.	3.8	25
148	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 237-243.	5.8	25
149	Antiphospholipid syndrome. <i>Arthritis Research and Therapy</i> , 2008, 10, 230.	3.5	24
150	Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1097-1102.	2.4	24
151	A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1550-1561.	5.6	24
152	Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behçet's diseases. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S117-22.	0.8	24
153	The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome. <i>Clinical Rheumatology</i> , 2007, 26, 2109-2114.	2.2	23
154	The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. <i>Genes and Immunity</i> , 2012, 13, 191-196.	4.1	23
155	Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2012, 11, 705-712.	5.8	23
156	Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis. <i>Medicine (United States)</i> , 2010, 89, 1070-1075.	1.0	23
157	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
158	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. <i>Respiratory Research</i> , 2022, 23, 37.	3.6	23
159	Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. <i>Thrombosis and Haemostasis</i> , 2009, 101, 312-316.	3.4	22
160	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. <i>Medicina Clínica</i> , 2018, 151, 215-222.	0.6	22
161	Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 469-473.	1.1	22
162	Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis. <i>American Journal of Nephrology</i> , 2016, 44, 439-446.	3.1	21

#	ARTICLE	IF	CITATIONS
163	Behçet's disease and genetic interactions between HLA-B*51 and variants in genes of autoinflammatory syndromes. <i>Scientific Reports</i> , 2019, 9, 2777.	3.3	21
164	Effects of Î2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. <i>Arthritis and Rheumatism</i> , 2002, 46, 3283-3289.	6.7	20
165	Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 85-88.	5.8	20
166	Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 26-30.	2.7	20
167	First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. <i>Lupus Science and Medicine</i> , 2016, 3, e000153.	2.7	20
168	Caracterización de los pacientes con uveítis remitidos a una unidad multidisciplinar de referencia en el norte de España. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2017, 92, 202-209.	0.2	20
169	Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020, 6, e001192.	3.8	20
170	Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. <i>Scientific Reports</i> , 2020, 10, 11567.	3.3	20
171	Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. <i>Journal of Clinical Rheumatology</i> , 2002, 8, 157-65.	0.9	20
172	Lymphoplasmacytic lymphoma causing light chain cast nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 450-453.	0.7	19
173	Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 1895-1896.	2.0	19
174	Renal Transplantation in Systemic Lupus Erythematosus: Outcome and Prognostic Factors in 50 Cases from a Single Centre. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	19
175	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017, 16, 1109-1114.	5.8	19
176	Treat-to-target in systemic lupus erythematosus: Where are we?. <i>European Journal of Internal Medicine</i> , 2020, 74, 29-34.	2.2	19
177	Mortality and long term survival prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit: a retrospective study. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 338-44.	0.8	19
178	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021, 10, 783.	2.4	18
179	The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. <i>Journal of Nephrology</i> , 2021, 34, 1897-1905.	2.0	18
180	Behçet's disease and hereditary periodic fever syndromes: casual association or causal relationship?. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, S64-6.	0.8	18

#	ARTICLE	IF	CITATIONS
181	GIMAP and Behçet disease: no association in the European population: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1433-1434.	0.9	17
182	Variants of the <i>IFI16</i> Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to Behçet Disease. <i>Journal of Rheumatology</i> , 2015, 42, 695-701.	2.0	17
183	Association of Functional Polymorphisms of KIR3DL1/DS1 With Behçet's Disease. <i>Frontiers in Immunology</i> , 2019, 10, 2755.	4.8	17
184	COVID-19 and Behçet's disease: clinical case series. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e41-e41.	0.9	17
185	Registry of the Spanish network of Behçet's disease: a descriptive analysis of 496 patients. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S33-9.	0.8	17
186	Catastrophic antiphospholipid syndrome triggered by fulminant disseminated herpes simplex infection in a patient with systemic lupus erythematosus. <i>Lupus</i> , 2012, 21, 1359-1361.	1.6	16
187	Congenital heart block related to maternal autoantibodies: descriptive analysis of a series of 18 cases from a single center. <i>Clinical Rheumatology</i> , 2016, 35, 351-356.	2.2	16
188	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1987-1993.	3.0	16
189	Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1299-1306.	3.4	16
190	Integrative epigenomics in Sjögren's syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. <i>Scientific Reports</i> , 2021, 11, 23292.	3.3	16
191	Saturación del servicio de urgencias: factores asociados y cuantificación. <i>Medicina Clínica</i> , 2003, 121, 167-172.	0.6	15
192	Morbidity and mortality in the antiphospholipid syndrome. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 413-417.	2.6	15
193	Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies. <i>Journal of Reproductive Immunology</i> , 2010, 86, 133-140.	1.9	15
194	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2050-2052.	0.9	15
195	Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. <i>Immunobiology</i> , 2017, 222, 620-630.	1.9	15
196	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , 2020, 29, 1050-1059.	1.6	15
197	Beta-2-Glycoprotein I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019. <i>ACR Open Rheumatology</i> , 2021, 3, 267-276.	2.1	15
198	The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1039-1047.	3.7	14

#	ARTICLE	IF	CITATIONS
199	Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo?. <i>Trends in Immunology</i> , 2008, 29, 280-289.	6.8	14
200	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2009, 41, e4-e7.	0.9	14
201	Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 601-614.	1.8	14
202	Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 164-171.	1.2	14
203	Documento de recomendaciones de tratamiento de la uveítis anterior no infecciosa. <i>Medicina Clínica</i> , 2017, 149, 552.e1-552.e12.	0.6	14
204	Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases. <i>Medicine (United States)</i> , 2020, 99, e18589.	1.0	14
205	Quality and effectiveness of an emergency department during weekends. <i>Emergency Medicine Journal</i> , 2004, 21, 573-574.	1.0	13
206	The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 169, 128-134.	1.7	13
207	Spanish scleroderma risk score (RESCLESORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. <i>Autoimmunity Reviews</i> , 2020, 19, 102507.	5.8	13
208	The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. <i>Clinical Rheumatology</i> , 2021, 40, 2057-2063.	2.2	13
209	Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. <i>Frontiers in Immunology</i> , 2021, 12, 754469.	4.8	13
210	Vascular involvement in Behçet's disease. <i>Israel Medical Association Journal</i> , 2002, 4, 614-6.	0.1	13
211	Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 926-32.	0.8	13
212	Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. <i>Autoimmunity Reviews</i> , 2012, 12, 289-294.	5.8	12
213	Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 97-104.	0.2	12
214	Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 1143-1149.	1.6	12
215	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. <i>Antibodies</i> , 2016, 5, 18.	2.5	12
216	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2857-2861.	3.0	12

#	ARTICLE	IF	CITATIONS
217	Plasma exchange in catastrophic antiphospholipid syndrome. <i>Presse Medicale</i> , 2019, 48, 347-353.	1.9	12
218	Post-exposure prophylaxis for HIV infection in sexual assault victims. <i>HIV Medicine</i> , 2020, 21, 43-52.	2.2	12
219	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R154.	3.5	11
220	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 102406.	5.8	11
221	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. <i>Journal of Rheumatology</i> , 2020, 47, 89-98.	2.0	11
222	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. <i>Scientific Reports</i> , 2020, 10, 11010.	3.3	11
223	Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. <i>Autoimmunity Reviews</i> , 2022, 21, 103014.	5.8	11
224	Development and implementation of the AIDA International Registry for patients with Behçet's disease. <i>Internal and Emergency Medicine</i> , 2022, 17, 1977-1986.	2.0	11
225	Eficacia de la ciclofosfamida endovenosa en el tratamiento de la enfermedad pulmonar intersticial asociada a la esclerosis sistémica. <i>Archivos De Bronconeumologia</i> , 2011, 47, 239-245.	0.8	10
226	Pars Plana Vitrectomy for Vitreoretinal Complications of Behçet's Uveitis. <i>European Journal of Ophthalmology</i> , 2013, 23, 119-128.	1.3	10
227	A virtual dairy herd as a tool to teach dairy production and management. <i>Journal of Dairy Science</i> , 2020, 103, 2896-2905.	3.4	10
228	Complicaciones y agudeza visual en los pacientes con uveítis en una unidad multidisciplinar de referencia del norte de España. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2019, 94, 419-425.	0.2	10
229	Catastrophic Antiphospholipid Syndrome - 20 Years Later. <i>Current Rheumatology Reviews</i> , 2013, 9, 73-80.	0.8	10
230	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1982-1986.	3.0	9
231	Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations. <i>Clinical Rheumatology</i> , 2016, 35, 695-699.	2.2	9
232	Association between allelic variants of the human glucocorticoid receptor gene and autoimmune diseases: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 449-456.	5.8	9
233	Autoantibodies, elevated cytokines, and neurocognitive abnormalities in offspring of women with systemic lupus erythematosus: comparison with healthy controls. <i>Clinical Rheumatology</i> , 2019, 38, 2529-2539.	2.2	9
234	Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms. <i>Journal of Rheumatology</i> , 2020, 47, 1275-1284.	2.0	9

#	ARTICLE	IF	CITATIONS
235	Usefulness of high-frequency ultrasonography in the evaluation and monitoring of sclerosing dermatoses: a cohort study. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 351-358.	1.3	9
236	Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 247-252.	0.2	9
237	ORIGINAL ARTICLE: Thrombin Activatable Fibrinolysis Inhibitor and Clot Lysis Time in Pregnant Patients with Antiphospholipid Syndrome: Relationship with Pregnancy Outcome and Thrombosis. <i>American Journal of Reproductive Immunology</i> , 2009, 62, 381-389.	1.2	8
238	Genotypes Coding for Low Serum Levels of Mannose-Binding Lectin Are Underrepresented among Individuals Suffering from Noninfectious Systemic Inflammatory Response Syndrome. <i>Vaccine Journal</i> , 2010, 17, 447-453.	3.1	8
239	Renal tubular acidosis type IV as a complication of lupus nephritis. <i>Lupus</i> , 2016, 25, 307-309.	1.6	8
240	LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. <i>Rheumatology International</i> , 2019, 39, 1875-1882.	3.0	8
241	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	1.6	8
242	Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes. <i>European Journal of Anaesthesiology</i> , 2021, 38, 916-922.	1.7	8
243	Catastrophic antiphospholipid syndrome: an orchestra with several musicians. <i>Israel Medical Association Journal</i> , 2014, 16, 585-6.	0.1	8
244	Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 98-105.	0.8	8
245	Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort. <i>Rheumatology</i> , 2023, 62, S182-S190.	1.9	8
246	Classification criteria for SLE: the latest-but not least-attempt. <i>Nature Reviews Rheumatology</i> , 2012, 8, 506-507.	8.0	7
247	The problems and pitfalls in systemic lupus erythematosus drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 525-527.	5.0	7
248	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	3.5	7
249	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. <i>Rheumatology</i> , 2020, 59, 3690-3699.	1.9	7
250	Belimumab, a BlyS-specific inhibitor for the treatment of systemic lupus erythematosus. <i>Drugs of Today</i> , 2010, 46, 891.	1.1	7
251	Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 466-72.	0.8	7
252	Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4946.	4.1	7

#	ARTICLE	IF	CITATIONS
253	Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
254	Management of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2010, 1, 15-22.	3.9	6
255	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 125-131.	0.3	6
256	Anti-“Polymyositis/Scl Antibodies in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e180-e188.	0.9	6
257	Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 40-47.	0.8	6
258	Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort). <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 40-44.	0.8	6
259	Gastrointestinal Involvement in Dermatomyositis. <i>Diagnostics</i> , 2022, 12, 1200.	2.6	6
260	Chapter 8 Systemic Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 105-116.	0.1	5
261	Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1279-1282.	3.4	5
262	Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES. <i>Revista Clínica Española</i> , 2017, 217, 7-14.	0.6	5
263	Brain abscess due to <i>Listeria monocytogenes</i> after HELLP syndrome in a patient with antiphospholipid syndrome. <i>Lupus</i> , 2017, 26, 1002-1004.	1.6	5
264	Oxigenador extracorpóreo de membrana eficaz en una paciente con miocarditis lámpica fulminante. <i>Revista Española De Cardiología</i> , 2017, 70, 1013-1014.	1.2	5
265	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. <i>RMD Open</i> , 2020, 6, e001355.	3.8	5
266	Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. <i>Lupus</i> , 2021, 30, 134-140.	1.6	5
267	Control del embarazo en pacientes con lupus eritematoso sistémico/síndrome antifosfolípido. parte 2: seguimiento del embarazo. <i>Reumatología Clínica</i> , 2021, 17, 125-131.	0.5	5
268	Hidroxiclороquina en el tratamiento del COVID-19: cómo utilizarla a la espera de evidencia científica concluyente. <i>Medicina Clínica</i> , 2020, 155, 134-135.	0.6	5
269	Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2081-2088.	2.9	5
270	Pulmonary Involvement in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2004, 2, 137-145.	0.1	4

#	ARTICLE	IF	CITATIONS
271	No evidence of association between functional polymorphisms located within <i>IL6R</i> and <i>IL6ST</i> genes and systemic sclerosis. <i>Tissue Antigens</i> , 2012, 80, 254-258.	1.0	4
272	Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. <i>Clinical Investigation</i> , 2015, 5, 561-571.	0.0	4
273	Autologous Hematopoietic Stem Cell Transplantation for Susac Syndrome. <i>Annals of Internal Medicine</i> , 2020, 173, 315-317.	3.9	4
274	Unidades y asistencia multidisciplinar de uveítis en los servicios de medicina interna en España: encuesta del Grupo de Enfermedades Autoinmunes Sistémicas. <i>Revista Clínica Española</i> , 2021, 221, 221-225.	0.6	4
275	Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines. <i>Expert Review of Hematology</i> , 2021, 14, 457-466.	2.2	4
276	Catastrophic antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 39-43.	0.1	4
277	Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. <i>Medicina Clínica</i> , 2021, 157, 247-252.	0.6	4
278	Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome. , 2002, , 169-188.		4
279	The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study. <i>Arthritis Research and Therapy</i> , 2022, 24, 9.	3.5	4
280	Chronic thromboembolic pulmonary hypertension in Behçet's disease: effectiveness of endarterectomy. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S79-81.	0.8	4
281	Lack of association of TNFAIP3 and JAK1 with Behçet's disease in the European population. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S36-9.	0.8	4
282	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.8	4
283	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. <i>European Journal of Internal Medicine</i> , 2022, 99, 19-21.	2.2	4
284	The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the "Catastrophic antiphospholipid syndrome registry". <i>Lupus</i> , 2022, 31, 1218-1225.	1.6	4
285	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 2022, 31, 1344-1354.	1.6	4
286	Current management of catastrophic antiphospholipid syndrome. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 297-303.	0.3	3
287	FRIO213...Anti-TNF therapy in refractory uveitis of behçet's syndrome. A multicenter study of 63 patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 386.1-386.	0.9	3
288	What is the best strategy in treating catastrophic antiphospholipid syndrome?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 245-255.	0.3	3

#	ARTICLE	IF	CITATIONS
289	Profile of patients with uveitis referred to a multidisciplinary unit in northern Spain. Archivos De La Sociedad Espanola De Oftalmologia, 2017, 92, 202-209.	0.2	3
290	Control del embarazo en pacientes con lupus eritematoso sistémico y síndrome antifosfolípido. Parte 1: Infertilidad, preservación ovárica y valoración preconcepcional. Documento de consenso de la Sociedad Española de Ginecología y Obstetricia (SEGO), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de Reumatología (SER). Reumatología Clínica, 2021, 17, 61-66.	0.5	3
291	Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 421-424.	0.6	3
292	Control del embarazo en pacientes con lupus eritematoso sistémico/síndrome antifosfolípido. Parte 3. Parto. Puerperio. Lactancia. Anticoncepción. Recién nacido. Reumatología Clínica, 2021, 17, 183-186.	0.5	3
293	Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: Childbirth. Puerperium. Breastfeeding contraception. Newborn. Reumatología Clínica (English) Tj ETQq1 1 0.784314 rgBT /@verlock	0.5	3
294	Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: Result of the COVID-19-GEAS patient survey. Archivos De La Sociedad Espanola De Oftalmologia, 2021, 96, 347-352.	0.2	3
295	Scleritis and sclerokeratitis associated with IgA vasculitis: A case series. American Journal of Ophthalmology Case Reports, 2021, 22, 101100.	0.7	3
296	Recent trends in the management of antiphospholipid syndrome (Hughes syndrome). Drugs of Today, 2010, 46, 39.	1.1	3
297	Presumed tuberculosis-related scleritis. British Journal of Ophthalmology, 2023, 107, 495-499.	3.9	3
298	Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. Clinical and Experimental Rheumatology, 2014, 32, S67-71.	0.8	3
299	Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center. Arthritis Research and Therapy, 2022, 24, 91.	3.5	3
300	Unusual manifestations of the antiphospholipid syndrome. International Journal of Clinical Rheumatology, 2009, 4, 189-202.	0.3	2
301	Mortality prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit. European Journal of Internal Medicine, 2013, 24, e114.	2.2	2
302	Successful Extracorporeal Membrane Oxygenation in a Patient With Fulminant Lupus Myocarditis. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1013-1014.	0.6	2
303	Systemic lupus erythematosus exacerbation following cessation of belimumab treatment: comments on the article by Furer et al. Scandinavian Journal of Rheumatology, 2017, 46, 250-251.	1.1	2
304	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina Clínica (English Edition), 2018, 151, 215-222.	0.2	2
305	Precision medicine and the antiphospholipid syndrome: what is the future?. Clinical Rheumatology, 2020, 39, 1015-1017.	2.2	2
306	Pregnancy control in patients with systemic lupus erythematosus and antiphospholipid syndrome. Part 1: Infertility, ovarian preservation and preconception assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER). Reumatología Clínica (English Edition), 2021, 17, 61-66.	0.3	2

#	ARTICLE	IF	CITATIONS
307	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , 2021, 22, 218-224.	2.2	2
308	Unilateral granulomatous mastitis in a pregnant woman as a first manifestation of sarcoidosis. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 406-408.	1.1	2
309	Causes of Hospitalization in Systemic Lupus Erythematosus: A Narrative Review. <i>Current Rheumatology Reviews</i> , 2021, 17, 29-40.	0.8	2
310	Antimalarial-induced retinal toxicity. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 132-143.	0.1	2
311	Obstetric outcomes in systemic sclerosis: looking inside the sealed box. <i>Rheumatology International</i> , 2021, , 1.	3.0	2
312	Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2010, 6, 3-11.	0.8	2
313	PTPN22 is not associated with Behçet's disease. Study spanning the complete gene region in the Spanish population and meta-analysis of the functional variant R620W. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S41-S45.	0.8	2
314	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 69-75.	0.8	2
315	The anti-phospholipid syndrome: 30 years in the forefront (1983-2013). <i>Rheumatology</i> , 2013, 52, 1347-1348.	1.9	1
316	Diagnosing catastrophic antiphospholipid syndrome: the necessity for clinical awareness. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 1-3.	0.3	1
317	Longitudinally extensive myelitis in a patient with characteristic autoantibody profile of systemic lupus erythematosus: a challenging etiological diagnosis. <i>Lupus</i> , 2014, 23, 1555-1556.	1.6	1
318	Fístulas arteriovenosas durales recurrentes en paciente con enfermedad de Behçet. <i>Neurología</i> , 2017, 32, 623-626.	0.7	1
319	Treatment of Catastrophic Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 243-255.	0.1	1
320	Thrombotic Manifestations of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 87-106.	0.1	1
321	All that glitters is not lupus. <i>Lupus</i> , 2018, 27, 1047-1048.	1.6	1
322	Complications and visual acuity of patients with uveitis: Epidemiological study in a reference unit in northern Spain. <i>Archivos De La Sociedad Espanola De Oftalmología</i> , 2019, 94, 419-425.	0.2	1
323	Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 30-41.	2.1	1
324	Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1591-1598.	1.8	1

#	ARTICLE	IF	CITATIONS
325	Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series. <i>Ocular Immunology and Inflammation</i> , 2020, , 1-6.	1.8	1
326	Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 134-135.	0.2	1
327	O31â€...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
328	Multidisciplinary care and units for uveitis in the internal medicine departments in Spain: Survey of the Systemic Autoimmune Diseases Group. <i>Revista Clínica Espan&#x00ed;nica Espan&#x00f5;la</i> , 2021, 221, 221-225.	0.5	1
329	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021, 60, e181-e183.	1.9	1
330	Non-criteria Manifestations of Antiphospholipid Syndrome: An Overview. <i>Spanish Journal of Medicine</i> , 2021, 1, .	0.1	1
331	Treat to target in systemic lupus erythematosus. <i>Revista Colombiana De ReumatologÃa</i> , 2021, 28, 101-106.	0.1	1
332	Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. <i>Revista Colombiana De ReumatologÃa</i> , 2021, 28, 82-89.	0.1	1
333	COVID-19 coagulopathy and antiphospholipid syndrome. <i>Revista Colombiana De ReumatologÃa</i> , 2022, 29, S25-S34.	0.1	1
334	VACOVEASÂ study, an observationalÂ survey onÂ the adverse events associated withÂCOVID-19 vaccines inÂ patients with systemic autoimmuneÂ diseases. <i>European Journal of Internal Medicine</i> , 2021, 93, 110-111.	2.2	1
335	15th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome Report. , 2017, , 307-316.		1
336	Identification of indoor fungal antigens in assessment of hypersensitivity pneumonitis â€“ an alternate approach. , 2019, , .		1
337	Hematological Abnormalities in the Antiphospholipid Syndrome. , 2002, , 259-270.		1
338	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
339	Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110547.	1.3	1
340	Association of CCR5Î³32 and BehÃset's disease: new data from a case-control study in the Spanish population and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S96-100.	0.8	1
341	Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 106-114.	0.8	1
342	The 4G/5G polymorphism of the type-1 plasminogen activator inhibitor gene is a determinant of disease phenotype and thrombotic events in patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2001, 120, A457.	1.3	0

#	ARTICLE	IF	CITATIONS
343	Treatment of ANCA-Associated Vasculitisâ€”Reply. JAMA - Journal of the American Medical Association, 2007, 298, 2739.	7.4	0
344	Chapter 4 Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2008, 8, 39-49.	0.1	0
345	Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases, 2008, 9, 95-101.	0.1	0
346	Editorial [Hot Topic: Organ Involvement in the Antiphospholipid Syndrome (Guest Editors: Gerard Tj ETQq0 0 0 rgBT /Overlock 10 Tf 00	0.8	0
347	Treatment of Antiphospholipid Syndrome. , 2011, , 1027-1042.		0
348	Therapeutic Perspectives in the Antiphospholipid Syndrome. Current Rheumatology Reviews, 2011, 7, 313-321.	0.8	0
349	Congenital heart block related with maternal autoimmune diseases: Descriptive analysis of a series of 17 cases. European Journal of Internal Medicine, 2013, 24, e130-e131.	2.2	0
350	FRIO338â€”Multicenter study of tumour necrosis factor alpha antagonists for refractory behÃ§etâ€™s uveitis in Spain. Annals of the Rheumatic Diseases, 2013, 72, A488.3-A489.	0.9	0
351	THU0278â€”Rituximab in Catastrophic Antiphospholipid Syndrome: A Potential Therapeutic Option. Annals of the Rheumatic Diseases, 2013, 72, A259.2-A260.	0.9	0
352	AB0631â€”Anti-Rna Polymerase III and anti Pm/Scl Antibodies: Prevalence and Clinical Associations in A Large Cohort of Spanish Patients with Systemic Sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 1014.2-1014.	0.9	0
353	FRIO418â€”Outcome of the Autoimmune Congenital Heart Block in 45 Babies from Anti-RO/LA (+) Mothers: Results from the Spanish Registry (Rebacc-Geas-Semi). Annals of the Rheumatic Diseases, 2015, 74, 578.1-578.	0.9	0
354	AB0009â€”The HLA Class I Region in BehÃ§et's Disease: Identifying the Most Relevant Amino Acid Positions. Annals of the Rheumatic Diseases, 2015, 74, 894.1-894.	0.9	0
355	SAT0534â€”Thrombosis and Re-Thrombosis Manifestations in Patients with BehÃ§et Disease. Descriptive Analysis from Regeb Cohort. Annals of the Rheumatic Diseases, 2015, 74, 853.2-854.	0.9	0
356	FRIO403â€”Heart Valvular Involvement in the Antiphospholipid Syndrome. An Echocardiographic Descriptive Study. Annals of the Rheumatic Diseases, 2015, 74, 572.2-572.	0.9	0
357	AB0718â€”Cardiac Tamponade and Severe Pericardial Effusion in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1138.2-1138.	0.9	0
358	SAT0544â€”Comparing New and Classical Diagnostic Criteria in BehÃ§et Disease (BD). Annals of the Rheumatic Diseases, 2015, 74, 857.2-857.	0.9	0
359	FRIO311â€”Neuropsychiatric Lupus: Combining Advanced Morphometric Methods, Diffusion Tensor Imaging and Conventional MRI Leads To The Pathways of Brain Abnormalities. Correlation with Clinical and Laboratory Data. Annals of the Rheumatic Diseases, 2016, 75, 547.3-548.	0.9	0
360	Rituximab action on the antiphospholipid antibodies in patients with thrombotic antiphospholipid syndrome. Medicina ClÃ¡nica (English Edition), 2016, 146, e69-e70.	0.2	0

#	ARTICLE	IF	CITATIONS
361	Cardiac Involvement in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, , 295-321.	0.1	0
362	Prognosis in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 281-294.	0.1	0
363	Cessation of oral anticoagulants in antiphospholipid syndrome. Lupus, 2017, 26, 1347-1348.	1.6	0
364	Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish Departments of Internal Medicine: The RELES study. Revista Colombiana De Reumatología, 2017, 217, 7-14.	0.5	0
365	Recurrent dural arteriovenous fistulas in a patient with Behçet's disease. Neurología (English) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.4	0
366	THU0549â€¦Systemic treatment for acute anterior uveitis (synthetic and biologic disease-modifying) Tj ETQq0 0 0 rgBT /Overlock 10 T		
367	THU0561â€¦Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome. , 2017, , .		0
368	Editorial al artículo: «Relación clínico-patológica en pacientes colombianos con nefritis lúpica». Revista Colombiana De Reumatología, 2017, 24, 197-198.	0.1	0
369	Editorial to article: «Clinico-pathologic relationship in Colombian patients with lupus nephritis» Revista Colombiana De Reumatología (English Edition), 2017, 24, 197-198.	0.0	0
370	FRI0602â€¦National recommendations on the use of immunomodulatory drugs in patients with non-infectious non-malignant anterior uveitis. , 2017, , .		0
371	THU0569â€¦Treatments of uveitis in a referral multidisciplinary unit in northern Spain. , 2017, , .		0
372	OP0231â€¦The effect of «triple therapy» with anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulins on the mortality of catastrophic antiphospholipid syndrome (CAPS) patients. , 2017, , .		0
373	Digestive Involvement in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 13, 227-241.	0.1	0
374	An update on isolated retinal vasculitis. Minerva Oftalmologica, 2017, 59, .	0.1	0
375	AB0561â€¦Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. , 2018, , .		0
376	AB0678â€¦Peripheral ulcerative keratitis associated to autoimmune systemic diseases: visual prognosis and occurrence while systemic disease in remission. , 2018, , .		0
377	Identification of Indoor Fungal Antigens in Assessment of Hypersensitivity Pneumonitis - an Alternate Approach. , 2019, , .		0
378	Catastrophic Antiphospholipid Syndrome. , 2019, , 493-500.		0

#	ARTICLE	IF	CITATIONS
379	THU0299â€¦PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇETâ€™S SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
380	FRI0270â€¦APREMILAST IN NON-ULCER MANIFESTATIONS IN BEHÇETâ€™S DISEASE. MULTICENTER STUDY OF 32 CASES IN CLINICAL PRACTICE. , 2019, , .		0
381	THU0573â€¦COMPLICATIONS AND ACTIVITY OF UVEITIS IN A MULTIDISCIPLINARY REFERENCE UNIT IN THE NORTH OF SPAIN. , 2019, , .		0
382	OPO282â€¦OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS) VS. WITH OBSTETRIC MORBIDITY RELATED WITH ANTIPHOSPHOLIPID ANTIBODIES (OMAPS): A SURVEY OF 1650 CASES FROM EUROAPS REGISTRY. , 2019, , .		0
383	SAT0240â€¦DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÇETâ€™S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
384	AB0214â€¦MUSCLE INVOLVEMENT IN SYSTEMIC SCLEROSIS. , 2019, , .		0
385	SAT0215â€¦APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHÇETâ€™S DISEASE. MULTICENTER STUDY OF 49 CASES IN CLINICAL PRACTICE. , 2019, , .		0
386	Le Relapsing Polychondritis Damage Index (RPDAM) : dÃ©veloppement dâ€™un score lâ€™sionnel au cours de la polychondrite atrophiante. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 122-127.	0.0	0
387	POS0767â€¦CLINICAL MANIFESTATIONS, TREATMENT, AND OUTCOMES OF â€œNON-CRITERIAâ€•ANTIPHOSPHOLIPID SYNDROME IN COMPARISON WITH DEFINITE ANTIPHOSPHOLIPID SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS. Annals of the Rheumatic Diseases, 2021, 80, 637-638.	0.9	0
388	AB0340â€¦PATIENTS WITH LABORATORY CRITERIA OF ANTIPHOSPHOLIPID SYNDROME AND â€œNON-CRITERIAâ€• MANIFESTATIONS: A MULTICENTER STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1195.1-1195.	0.9	0
389	POS1371â€¦BIOLOGICAL THERAPY IN REFRACTORY NEUROBEHÇETâ€™S DISEASE. MULTICENTER STUDY OF 42 PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 967-968.	0.9	0
390	POS1409â€¦AUTOMATED DETECTION OF SCLERODERMIFORM PATTERNS USING CAPILLARY.IO. Annals of the Rheumatic Diseases, 2021, 80, 987.2-988.	0.9	0
391	POS1408â€¦REPRODUCIBILITY OF A NEW AUTOMATIC SYSTEM (CAPILLARY.IO) IN THE ANALYSIS OF NAILFOLD CAPILLAROSCOPY IMAGES. Annals of the Rheumatic Diseases, 2021, 80, 987.1-987.	0.9	0
392	The antiphospholipid syndrome. Revista Colombiana De ReumatologÃ­a, 2021, 28, 166-176.	0.1	0
393	Bipolar disorder and Susac syndrome. International Clinical Psychopharmacology, 2021, Publish Ahead of Print, 305-309.	1.7	0
394	BehÇet Disease. , 2008, , 113-116.		0
395	Task Force Report on Catastrophic Antiphospholipid Syndrome. , 2012, , 181-193.		0
396	Task Force Report on Non-criteria Manifestations: Cardiac Valve Disease. , 2012, , 223-233.		0

#	ARTICLE	IF	CITATIONS
397	Experiencia en el tratamiento de las uveítis con agentes anti-TNF- α en la Unidad de Uveítis del Hospital Clínic de Barcelona. , 2012, , 91-96.		0
398	Heart Valve Lesions In The Antiphospholipid Syndrome. Current Rheumatology Reviews, 2012, 8, 161-165.	0.8	0
399	Heart Valve Surgery and the Antiphospholipid Syndrome. , 2013, , 321-329.		0
400	Behçet's Disease. , 2015, , 1-9.		0
401	Behçet's Disease. , 2016, , 202-210.		0
402	SAT0598â€¦Systematic literature review on the efficacy and safety of immunomodulatory drugs in patients with noninfectious intermediate and posterior uveitis, panuveitis and macular oedema. , 2018, , .		0
403	Late Breaking Abstract - SMOKING PREVALENCE AND CHARACTERIZATION OF PATIENTS AT DIAGNOSIS OF DIFFUSE INTERSTITIAL LUNG DISEASES. , 2018, , .		0
404	SAT0274â€¦DESCRIPTIVE ANALYSIS OF FLARES DURING THE LONG-TERM FOLLOW-UP OF PATIENTS WITH BEHÇET'S DISEASE INCLUDED IN REGEB COHORT. Annals of the Rheumatic Diseases, 2020, 79, 1081.2-1081.	0.9	0
405	THU0307â€¦RESPONSE OF BEHÇET'S REFRACTORY ORAL AND/OR GENITAL ULCERS TO APREMILAST IN COMBINATION VS MONOTHERAPY. NATIONAL MULTICENTER STUDY OF 51 CASES OF CLINICAL PRACTICE. Annals of the Rheumatic Diseases, 2020, 79, 382.2-382.	0.9	0
406	FRI0487â€¦APREMILAST IN MONOTHERAPY OR COMBINED IN NON-ULCER MANIFESTATIONS OF BEHÇET'S DISEASE. NATIONAL MULTICENTER STUDY OF 34 REFRACTORY CASES OF CLINICAL PRACTICE. Annals of the Rheumatic Diseases, 2020, 79, 841.1-842.	0.9	0
407	SAT0316â€¦ANTI-PM/SCL ANTIBODIES IN SYSTEMIC SCLEROSIS: CLINICAL ASSOCIATIONS IN THE RESCLE COHORT. Annals of the Rheumatic Diseases, 2020, 79, 1103.1-1104.	0.9	0
408	Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. Medicina Clínica (English Edition), 2020, 155, 220.e1-220.e12.	0.2	0
409	Clinical Manifestations and Diagnosis of Behçet's Syndrome. European Medical Journal Rheumatology, 0, , 94-104.	0.0	0
410	Connective tissue disease-associated interstitial lung diseases and interstitial pneumonia with autoimmune features: different entities?. , 2020, , .		0
411	Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: A study based on the catastrophic antiphospholipid syndrome registry. Lupus, 2022, 31, 194-201.	1.6	0
412	Thrombotic Microangiopathy: a Challenging Diagnosis Always. Israel Medical Association Journal, 2016, 18, 437-438.	0.1	0
413	Comparative study between two European inception cohorts of patients with early systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2020, 38, 925-932.	0.8	0
414	Lung involvement in SLE. Handbook of Systemic Autoimmune Diseases, 2022, , 41-53.	0.1	0

#	ARTICLE	IF	CITATIONS
415	Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. Medicina Clínica, 2022, , .	0.6	0
416	Patients with laboratory criteria of anti-phospholipid syndrome and "non-criteria" manifestations: a multicenter cohort. Scandinavian Journal of Rheumatology, 0, , 1-6.	1.1	0